Skip to main content
Top
Published in: Diabetologia 6/2007

01-06-2007 | Article

Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells

Authors: A. Abderrahmani, G. Niederhauser, D. Favre, S. Abdelli, M. Ferdaoussi, J. Y. Yang, R. Regazzi, C. Widmann, G. Waeber

Published in: Diabetologia | Issue 6/2007

Login to get access

Abstract

Aims/hypothesis

We explored the potential adverse effects of pro-atherogenic oxidised LDL-cholesterol particles on beta cell function.

Materials and methods

Isolated human and rat islets and different insulin-secreting cell lines were incubated with human oxidised LDL with or without HDL particles. The insulin level was monitored by ELISA, real-time PCR and a rat insulin promoter construct linked to luciferase gene reporter. Cell apoptosis was determined by scoring cells displaying pycnotic nuclei.

Results

Prolonged incubation with human oxidised LDL particles led to a reduction in preproinsulin expression levels, whereas the insulin level was preserved in the presence of native LDL-cholesterol. The loss of insulin production occurred at the transcriptional levels and was associated with an increase in activator protein-1 transcriptional activity. The rise in activator protein-1 activity resulted from activation of c-Jun N-terminal kinases (JNK, now known as mitogen-activated protein kinase 8 [MAPK8]) due to a subsequent decrease in islet-brain 1 (IB1; now known as MAPK8 interacting protein 1) levels. Consistent with the pro-apoptotic role of the JNK pathway, oxidised LDL also induced a twofold increase in the rate of beta cell apoptosis. Treatment of the cells with JNK inhibitor peptides or HDL countered the effects mediated by oxidised LDL.

Conclusions/interpretation

These data provide strong evidence that oxidised LDL particles exert deleterious effects in the progression of beta cell failure in diabetes and that these effects can be countered by HDL particles.
Appendix
Available only for authorised users
Literature
1.
go back to reference Donath MY, Ehses JA, Maedler K et al (2005) Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54(Suppl 2):S108–S113PubMedCrossRef Donath MY, Ehses JA, Maedler K et al (2005) Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54(Suppl 2):S108–S113PubMedCrossRef
2.
go back to reference Kaneto H, Kawamori D, Matsuoka TA et al (2005) Oxidative stress and pancreatic beta-cell dysfunction. Am J Ther 12:529–533PubMedCrossRef Kaneto H, Kawamori D, Matsuoka TA et al (2005) Oxidative stress and pancreatic beta-cell dysfunction. Am J Ther 12:529–533PubMedCrossRef
3.
go back to reference Kajimoto Y, Kaneto H (2004) Role of oxidative stress in pancreatic beta-cell dysfunction. Ann N Y Acad Sci 1011:168–176PubMedCrossRef Kajimoto Y, Kaneto H (2004) Role of oxidative stress in pancreatic beta-cell dysfunction. Ann N Y Acad Sci 1011:168–176PubMedCrossRef
4.
go back to reference Kaneto H, Nakatani Y, Kawamori D et al (2005) Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic beta-cell dysfunction and insulin resistance. Int J Biochem Cell Biol 37:1595–1608PubMedCrossRef Kaneto H, Nakatani Y, Kawamori D et al (2005) Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic beta-cell dysfunction and insulin resistance. Int J Biochem Cell Biol 37:1595–1608PubMedCrossRef
5.
go back to reference Derijard B, Hibi M, Wu IH et al (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025–1037PubMedCrossRef Derijard B, Hibi M, Wu IH et al (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025–1037PubMedCrossRef
6.
go back to reference Hibi M, Lin A, Smeal T et al (1993) Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7:2135–2148PubMedCrossRef Hibi M, Lin A, Smeal T et al (1993) Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7:2135–2148PubMedCrossRef
7.
go back to reference Kaneto H, Xu G, Fujii N et al (2002) Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 277:30010–30018PubMedCrossRef Kaneto H, Xu G, Fujii N et al (2002) Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 277:30010–30018PubMedCrossRef
8.
go back to reference Bonny C, Oberson A, Negri S et al (2001) Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50:77–82PubMedCrossRef Bonny C, Oberson A, Negri S et al (2001) Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50:77–82PubMedCrossRef
9.
go back to reference Bonny C, Nicod P, Waeber G (1998) IB1, a JIP-1-related nuclear protein present in insulin-secreting cells. J Biol Chem 273:1843–1846PubMedCrossRef Bonny C, Nicod P, Waeber G (1998) IB1, a JIP-1-related nuclear protein present in insulin-secreting cells. J Biol Chem 273:1843–1846PubMedCrossRef
10.
go back to reference Dickens M, Rogers JS, Cavanagh J et al (1997) A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277:693–696PubMedCrossRef Dickens M, Rogers JS, Cavanagh J et al (1997) A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277:693–696PubMedCrossRef
11.
go back to reference Waeber G, Delplanque J, Bonny C et al (2000) The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nat Genet 24:291–295PubMedCrossRef Waeber G, Delplanque J, Bonny C et al (2000) The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nat Genet 24:291–295PubMedCrossRef
12.
go back to reference Zhang S, Liu J, MacGibbon G, Dragunow M et al (2002) Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet beta-cells. J Mol Biol 324:271–285PubMedCrossRef Zhang S, Liu J, MacGibbon G, Dragunow M et al (2002) Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet beta-cells. J Mol Biol 324:271–285PubMedCrossRef
13.
go back to reference Henderson E, Stein R (1994) c-jun inhibits transcriptional activation by the insulin enhancer, and the insulin control element is the target of control. Mol Cell Biol 14:655–662PubMed Henderson E, Stein R (1994) c-jun inhibits transcriptional activation by the insulin enhancer, and the insulin control element is the target of control. Mol Cell Biol 14:655–662PubMed
14.
go back to reference Robinson GL, Henderson E, Massari ME et al (1995) c-jun inhibits insulin control element-mediated transcription by affecting the transactivation potential of the E2A gene products. Mol Cell Biol 15:1398–1404PubMed Robinson GL, Henderson E, Massari ME et al (1995) c-jun inhibits insulin control element-mediated transcription by affecting the transactivation potential of the E2A gene products. Mol Cell Biol 15:1398–1404PubMed
15.
go back to reference Bonny C, Oberson A, Steinmann M et al (2000) IB1 reduces cytokine-induced apoptosis of insulin-secreting cells. J Biol Chem 275:16466–16472PubMedCrossRef Bonny C, Oberson A, Steinmann M et al (2000) IB1 reduces cytokine-induced apoptosis of insulin-secreting cells. J Biol Chem 275:16466–16472PubMedCrossRef
16.
go back to reference Tawadros T, Formenton A, Dudler J et al (2002) The scaffold protein IB1/JIP-1 controls the activation of JNK in rat stressed urothelium. J Cell Sci 115:385–393PubMed Tawadros T, Formenton A, Dudler J et al (2002) The scaffold protein IB1/JIP-1 controls the activation of JNK in rat stressed urothelium. J Cell Sci 115:385–393PubMed
17.
go back to reference Allaman-Pillet N, Storling J, Oberson A et al (2003) Calcium- and proteasome-dependent degradation of the JNK scaffold protein islet-brain 1. J Biol Chem 278:48720–48726PubMedCrossRef Allaman-Pillet N, Storling J, Oberson A et al (2003) Calcium- and proteasome-dependent degradation of the JNK scaffold protein islet-brain 1. J Biol Chem 278:48720–48726PubMedCrossRef
18.
go back to reference Cullen P, von Eckardstein A, Souris S et al (1999) Dyslipidaemia and cardiovascular risk in diabetes. Diabetes Obes Metab 1:189–198PubMedCrossRef Cullen P, von Eckardstein A, Souris S et al (1999) Dyslipidaemia and cardiovascular risk in diabetes. Diabetes Obes Metab 1:189–198PubMedCrossRef
19.
go back to reference Rohrer L, Hersberger M, von Eckardstein A (2004) High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15:269–278PubMedCrossRef Rohrer L, Hersberger M, von Eckardstein A (2004) High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15:269–278PubMedCrossRef
20.
go back to reference Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749PubMedCrossRef Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749PubMedCrossRef
21.
go back to reference Parthasarathy S, Wieland E, Steinberg D (1989) A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 86:1046–1050PubMedCrossRef Parthasarathy S, Wieland E, Steinberg D (1989) A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 86:1046–1050PubMedCrossRef
22.
go back to reference Brown MS, Goldstein JL (1983) Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J Clin Invest 72:743–747PubMedCrossRef Brown MS, Goldstein JL (1983) Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J Clin Invest 72:743–747PubMedCrossRef
23.
go back to reference Goldstein JL, Anderson RG, Brown MS (1979) Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature 279:679–685PubMedCrossRef Goldstein JL, Anderson RG, Brown MS (1979) Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature 279:679–685PubMedCrossRef
24.
go back to reference Okajima F, Kurihara M, Ono C et al (2005) Oxidized but not acetylated low-density lipoprotein reduces preproinsulin mRNA expression and secretion of insulin from HIT-T15 cells. Biochim Biophys Acta 1687:173–180PubMed Okajima F, Kurihara M, Ono C et al (2005) Oxidized but not acetylated low-density lipoprotein reduces preproinsulin mRNA expression and secretion of insulin from HIT-T15 cells. Biochim Biophys Acta 1687:173–180PubMed
25.
go back to reference Lin SJ, Shyue SK, Liu PL et al (2004) Adenovirus-mediated overexpression of catalase attenuates oxLDL-induced apoptosis in human aortic endothelial cells via AP-1 and C-Jun N-terminal kinase/extracellular signal-regulated kinase mitogen-activated protein kinase pathways. J Mol Cell Cardiol 36:129–139PubMedCrossRef Lin SJ, Shyue SK, Liu PL et al (2004) Adenovirus-mediated overexpression of catalase attenuates oxLDL-induced apoptosis in human aortic endothelial cells via AP-1 and C-Jun N-terminal kinase/extracellular signal-regulated kinase mitogen-activated protein kinase pathways. J Mol Cell Cardiol 36:129–139PubMedCrossRef
26.
go back to reference Maziere C, Morliere P, Santus R et al (2004) Inhibition of insulin signaling by oxidized low density lipoprotein. Protective effect of the antioxidant vitamin E. Atherosclerosis 175:23–30PubMedCrossRef Maziere C, Morliere P, Santus R et al (2004) Inhibition of insulin signaling by oxidized low density lipoprotein. Protective effect of the antioxidant vitamin E. Atherosclerosis 175:23–30PubMedCrossRef
27.
go back to reference Stocker R, Keaney JF Jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84:1381–1478PubMedCrossRef Stocker R, Keaney JF Jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84:1381–1478PubMedCrossRef
28.
go back to reference Roehrich ME, Mooser V, Lenain V et al (2003) Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 278:18368–18375PubMedCrossRef Roehrich ME, Mooser V, Lenain V et al (2003) Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 278:18368–18375PubMedCrossRef
29.
go back to reference Sutton R, Peters M, McShane P et al (1986) Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation 42:689–691PubMedCrossRef Sutton R, Peters M, McShane P et al (1986) Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation 42:689–691PubMedCrossRef
30.
go back to reference Abderrahmani A, Cheviet S, Ferdaoussi M et al (2006) ICER induced by hyperglycemia represses the expression of genes essential for insulin exocytosis. EMBO J 25:977–986PubMedCrossRef Abderrahmani A, Cheviet S, Ferdaoussi M et al (2006) ICER induced by hyperglycemia represses the expression of genes essential for insulin exocytosis. EMBO J 25:977–986PubMedCrossRef
31.
go back to reference Steinbrecher UP, Parthasarathy S, Leake DS et al (1984) Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81:3883–3887PubMedCrossRef Steinbrecher UP, Parthasarathy S, Leake DS et al (1984) Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81:3883–3887PubMedCrossRef
32.
go back to reference Cnop M, Hannaert JC, Grupping AY et al (2002) Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 143:3449–3453PubMedCrossRef Cnop M, Hannaert JC, Grupping AY et al (2002) Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 143:3449–3453PubMedCrossRef
33.
go back to reference Scheidegger KJ, Cenni B, Picard D et al (2000) Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells. Mechanisms for its atheroprotective effects. J Biol Chem 275:38921–38928PubMedCrossRef Scheidegger KJ, Cenni B, Picard D et al (2000) Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells. Mechanisms for its atheroprotective effects. J Biol Chem 275:38921–38928PubMedCrossRef
34.
go back to reference Karlsson O, Edlund T, Moss JB et al (1987) A mutational analysis of the insulin gene transcription control region: expression in beta cells is dependent on two related sequences within the enhancer. Proc Natl Acad Sci USA 84:8819–8823PubMedCrossRef Karlsson O, Edlund T, Moss JB et al (1987) A mutational analysis of the insulin gene transcription control region: expression in beta cells is dependent on two related sequences within the enhancer. Proc Natl Acad Sci USA 84:8819–8823PubMedCrossRef
35.
go back to reference Whelan J, Poon D, Weil PA et al (1989) Pancreatic beta-cell-type-specific expression of the rat insulin II gene is controlled by positive and negative cellular transcriptional elements. Mol Cell Biol 9:3253–3259PubMed Whelan J, Poon D, Weil PA et al (1989) Pancreatic beta-cell-type-specific expression of the rat insulin II gene is controlled by positive and negative cellular transcriptional elements. Mol Cell Biol 9:3253–3259PubMed
36.
37.
go back to reference Go YM, Levonen AL, Moellering D et al (2001) Endothelial NOS-dependent activation of c-Jun NH(2)-terminal kinase by oxidized low-density lipoprotein. Am J Physiol Heart Circ Physiol 281:H2705–H2713PubMed Go YM, Levonen AL, Moellering D et al (2001) Endothelial NOS-dependent activation of c-Jun NH(2)-terminal kinase by oxidized low-density lipoprotein. Am J Physiol Heart Circ Physiol 281:H2705–H2713PubMed
38.
go back to reference Wu ZL, Wang YC, Zhou Q et al (2003) Oxidized LDL induces transcription factor activator protein-1 in rat mesangial cells. Cell Biochem Funct 21:249–256PubMedCrossRef Wu ZL, Wang YC, Zhou Q et al (2003) Oxidized LDL induces transcription factor activator protein-1 in rat mesangial cells. Cell Biochem Funct 21:249–256PubMedCrossRef
39.
go back to reference Tawadros T, Martin D, Abderrahmani A et al (2005) IB1/JIP-1 controls JNK activation and increased during prostatic LNCaP cells neuroendocrine differentiation. Cell Signal 17:929–939PubMedCrossRef Tawadros T, Martin D, Abderrahmani A et al (2005) IB1/JIP-1 controls JNK activation and increased during prostatic LNCaP cells neuroendocrine differentiation. Cell Signal 17:929–939PubMedCrossRef
40.
go back to reference Haefliger JA, Tawadros T, Meylan L et al (2003) The scaffold protein IB1/JIP-1 is a critical mediator of cytokine-induced apoptosis in pancreatic beta cells. J Cell Sci 116:1463–1469PubMedCrossRef Haefliger JA, Tawadros T, Meylan L et al (2003) The scaffold protein IB1/JIP-1 is a critical mediator of cytokine-induced apoptosis in pancreatic beta cells. J Cell Sci 116:1463–1469PubMedCrossRef
41.
go back to reference Chen J, Mehta JL, Haider N et al (2004) Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 94:269–270CrossRef Chen J, Mehta JL, Haider N et al (2004) Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 94:269–270CrossRef
42.
go back to reference Grupping AY, Cnop M, Van Schravendijk CF et al (1997) Low density lipoprotein binding and uptake by human and rat islet beta cells. Endocrinology 138:4064–4068PubMedCrossRef Grupping AY, Cnop M, Van Schravendijk CF et al (1997) Low density lipoprotein binding and uptake by human and rat islet beta cells. Endocrinology 138:4064–4068PubMedCrossRef
43.
go back to reference Inagaki N, Maekawa T, Sudo T et al (1992) c-Jun represses the human insulin promoter activity that depends on multiple cAMP response elements. Proc Natl Acad Sci USA 89:1045–1049PubMedCrossRef Inagaki N, Maekawa T, Sudo T et al (1992) c-Jun represses the human insulin promoter activity that depends on multiple cAMP response elements. Proc Natl Acad Sci USA 89:1045–1049PubMedCrossRef
44.
go back to reference Whitmarsh AJ, Davis RJ (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74:589–607PubMedCrossRef Whitmarsh AJ, Davis RJ (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74:589–607PubMedCrossRef
45.
go back to reference Dobreva I, Waeber G, Widmann C (2006) Lipoproteins and mitogen-activated protein kinase signaling: a role in atherogenesis? Curr Opin Lipidol 17:110–121PubMedCrossRef Dobreva I, Waeber G, Widmann C (2006) Lipoproteins and mitogen-activated protein kinase signaling: a role in atherogenesis? Curr Opin Lipidol 17:110–121PubMedCrossRef
46.
go back to reference Ammendrup A, Maillard A, Nielsen K et al (2000) The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells. Diabetes 49:1468–1476PubMedCrossRef Ammendrup A, Maillard A, Nielsen K et al (2000) The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells. Diabetes 49:1468–1476PubMedCrossRef
47.
go back to reference Estus S, Zaks WJ, Freeman RS et al (1994) Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol 127:1717–1727PubMedCrossRef Estus S, Zaks WJ, Freeman RS et al (1994) Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol 127:1717–1727PubMedCrossRef
48.
go back to reference Hersberger M, von Eckardstein A (2003) Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment. Drugs 63:1907–1945PubMedCrossRef Hersberger M, von Eckardstein A (2003) Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment. Drugs 63:1907–1945PubMedCrossRef
49.
go back to reference Navab M, Berliner JA, Subbanagounder G et al (2001) HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21:481–488PubMed Navab M, Berliner JA, Subbanagounder G et al (2001) HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21:481–488PubMed
50.
go back to reference Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473–480PubMed Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473–480PubMed
Metadata
Title
Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells
Authors
A. Abderrahmani
G. Niederhauser
D. Favre
S. Abdelli
M. Ferdaoussi
J. Y. Yang
R. Regazzi
C. Widmann
G. Waeber
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0642-z

Other articles of this Issue 6/2007

Diabetologia 6/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine